Eoin P. Flanagan, M.B., B.Ch.

Closed for Enrollment

• A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Rochester, Minn.

  To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

• A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab as Monotherapy or In Addition to Baseline Therapy in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (MOGAD) Rochester, Minn., Scottsdale/Phoenix, Ariz.

  The purpose of this study is to evaluate the effectiveness, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo as monotherapy or in addition (add-on) to baseline/background ISTs for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) relapse prevention.

   

• A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) (cosMOG) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The purpose of the study is to evalute the effectiveness, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).